Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report)'s stock price traded down 5.4% during trading on Friday . The company traded as low as $8.10 and last traded at $8.54. 70,762 shares were traded during trading, an increase of 106% from the average session volume of 34,363 shares. The stock had previously closed at $9.03.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating and issued a $75.00 price target on shares of Aligos Therapeutics in a report on Wednesday.
Check Out Our Latest Stock Report on ALGS
Aligos Therapeutics Stock Down 7.0 %
The firm has a 50 day moving average price of $10.69 and a 200 day moving average price of $13.65. The stock has a market cap of $656.12 million, a PE ratio of -6.56 and a beta of 2.16.
Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The business had revenue of $1.06 million during the quarter. During the same quarter in the prior year, the firm posted ($10.75) EPS. Equities analysts forecast that Aligos Therapeutics, Inc. will post -8.2 earnings per share for the current year.
Institutional Trading of Aligos Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of ALGS. Acadian Asset Management LLC lifted its stake in shares of Aligos Therapeutics by 17.6% during the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company's stock worth $644,000 after purchasing an additional 98,628 shares during the last quarter. Armistice Capital LLC lifted its position in shares of Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company's stock valued at $2,540,000 after buying an additional 363,000 shares during the last quarter. Finally, Opaleye Management Inc. lifted its position in shares of Aligos Therapeutics by 25.7% during the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company's stock valued at $1,597,000 after buying an additional 333,000 shares during the last quarter. Institutional investors own 60.43% of the company's stock.
About Aligos Therapeutics
(
Get Free Report)
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Featured Stories
Before you consider Aligos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aligos Therapeutics wasn't on the list.
While Aligos Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
